| Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations PK Paik, E Felip, R Veillon, H Sakai, AB Cortot, MC Garassino, J Mazieres, ... New England Journal of Medicine 383 (10), 931-943, 2020 | 648 | 2020 |
| Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial T Cascone, WN William Jr, A Weissferdt, CH Leung, HY Lin, A Pataer, ... Nature medicine 27 (3), 504-514, 2021 | 443 | 2021 |
| Effects of RAS on the genesis of embryonal rhabdomyosarcoma DM Langenau, MD Keefe, NY Storer, JR Guyon, JL Kutok, X Le, ... Genes & development 21 (11), 1382-1395, 2007 | 369 | 2007 |
| Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC X Le, S Puri, MV Negrao, MB Nilsson, J Robichaux, T Boyle, JK Hicks, ... Clinical Cancer Research 24 (24), 6195-6203, 2018 | 343 | 2018 |
| Structure-based classification predicts drug response in EGFR-mutant NSCLC JP Robichaux, X Le, RSK Vijayan, JK Hicks, S Heeke, YY Elamin, HY Lin, ... Nature 597 (7878), 732-737, 2021 | 241 | 2021 |
| Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC): Clinical and correlative results from the NEOSTAR study. T Cascone, WN William, A Weissferdt, HY Lin, CH Leung, BW Carter, ... Journal of Clinical Oncology 37 (15_suppl), 8504-8504, 2019 | 203 | 2019 |
| Heat shock-inducible Cre/Lox approaches to induce diverse types of tumors and hyperplasia in transgenic zebrafish X Le, DM Langenau, MD Keefe, JL Kutok, DS Neuberg, LI Zon Proceedings of the National Academy of Sciences 104 (22), 9410-9415, 2007 | 200 | 2007 |
| Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC X Le, M Nilsson, J Goldman, M Reck, K Nakagawa, T Kato, LP Ares, ... Journal of Thoracic Oncology 16 (2), 205-215, 2021 | 184 | 2021 |
| Comprehensive analysis of genetic ancestry and its molecular correlates in cancer J Carrot-Zhang, N Chambwe, JS Damrauer, TA Knijnenburg, ... Cancer Cell 37 (5), 639-654. e6, 2020 | 177 | 2020 |
| Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity JP Robichaux, YY Elamin, RSK Vijayan, MB Nilsson, L Hu, J He, F Zhang, ... Cancer Cell 36 (4), 444-457. e7, 2019 | 158 | 2019 |
| Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3–PD-L1≥ 50% expression in lung adenocarcinoma D Rangachari, PA VanderLaan, M Shea, X Le, MS Huberman, ... Journal of thoracic oncology 12 (5), 878-883, 2017 | 144 | 2017 |
| Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer MV Negrao, F Skoulidis, M Montesion, K Schulze, I Bara, V Shen, H Xu, ... Journal for immunotherapy of cancer 9 (8), 2021 | 138 | 2021 |
| Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC L Hong, MV Negrao, SS Dibaj, R Chen, A Reuben, JM Bohac, X Liu, ... Journal of Thoracic Oncology 15 (9), 1449-1459, 2020 | 130 | 2020 |
| Systematic functional characterization of resistance to PI3K inhibition in breast cancer X Le, R Antony, P Razavi, DJ Treacy, F Luo, M Ghandi, P Castel, ... Cancer discovery 6 (10), 1134-1147, 2016 | 125 | 2016 |
| A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components MB Nilsson, H Sun, J Robichaux, M Pfeifer, U McDermott, J Travers, ... Science translational medicine 12 (559), eaaz4589, 2020 | 121 | 2020 |
| Poziotinib in non–small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 trial X Le, R Cornelissen, M Garassino, JM Clarke, N Tchekmedyian, ... Journal of Clinical Oncology 40 (7), 710, 2022 | 98 | 2022 |
| Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. X Le, JW Goldman, JM Clarke, N Tchekmedyian, Z Piotrowska, D Chu, ... Journal of Clinical Oncology 38 (15_suppl), 9514-9514, 2020 | 96 | 2020 |
| Phase II study of tepotinib in NSCLC patients with METex14 mutations. PK Paik, R Veillon, AB Cortot, E Felip, H Sakai, J Mazieres, F Griesinger, ... Journal of Clinical Oncology 37 (15_suppl), 9005-9005, 2019 | 84 | 2019 |
| Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy SA Patel, MB Nilsson, X Le, T Cascone, RK Jain, JV Heymach Clinical Cancer Research 29 (1), 30-39, 2023 | 77 | 2023 |
| Characterization of the immune landscape of EGFR-mutant NSCLC identifies CD73/adenosine pathway as a potential therapeutic target X Le, MV Negrao, A Reuben, L Federico, L Diao, D McGrail, M Nilsson, ... Journal of thoracic oncology 16 (4), 583-600, 2021 | 72 | 2021 |
